Induction Therapy in Renal Transplantation: Why? What Agent? What Dose? We May Never Know.
作者信息
Wiseman Alexander C
机构信息
Division of Renal Diseases and Hypertension, Transplant Center, University of Colorado, Denver, Colorado
出版信息
Clin J Am Soc Nephrol. 2015 Jun 5;10(6):923-5. doi: 10.2215/CJN.03800415. Epub 2015 May 15.
Abstract
摘要
相似文献
1
Induction Therapy in Renal Transplantation: Why? What Agent? What Dose? We May Never Know.肾移植中的诱导治疗：为何进行？使用何种药物？使用多大剂量？我们可能永远无法知晓。
Clin J Am Soc Nephrol. 2015 Jun 5;10(6):923-5. doi: 10.2215/CJN.03800415. Epub 2015 May 15.
2
Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance.活体供肾移植中使用他克莫司和霉酚酸酯并联合或不联合类固醇维持治疗的诱导疗法。
Clin J Am Soc Nephrol. 2015 Jun 5;10(6):1041-9. doi: 10.2215/CJN.08710814. Epub 2015 May 15.
3
Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.兔抗胸腺细胞球蛋白或巴利昔单抗诱导治疗在肾移植后快速撤停激素（Harmony）：一项开放标签、多中心、随机对照试验。
Lancet. 2016 Dec 17;388(10063):3006-3016. doi: 10.1016/S0140-6736(16)32187-0. Epub 2016 Nov 19.
4
Rejection rate in living donor kidney transplantation with and without basiliximab in tacrolimus/mycophenolate mofetil-based protocol.
Transplant Proc. 2003 Mar;35(2):653-4. doi: 10.1016/s0041-1345(03)00024-1.
5
Thymoglobulin Versus Basiliximab Induction Therapy in Low-Risk Kidney Transplant Recipients: A Single-Center Experience.低风险肾移植受者中胸腺球蛋白与巴利昔单抗诱导治疗的单中心经验
Transplant Proc. 2018 Jun;50(5):1285-1288. doi: 10.1016/j.transproceed.2018.02.088.
6
Acute Rejection Rates and Graft Outcomes According to Induction Regimen among Recipients of Kidneys from Deceased Donors Treated with Tacrolimus and Mycophenolate.根据他克莫司和霉酚酸酯治疗的已故供体肾移植受者的诱导方案，急性排斥反应率和移植物结局
Clin J Am Soc Nephrol. 2016 Sep 7;11(9):1650-1661. doi: 10.2215/CJN.13171215. Epub 2016 Jun 30.
7
Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids.吗替麦考酚酯和皮质类固醇治疗的肾移植受者中，用胸腺球蛋白诱导和西罗莫司与他克莫司比较。
Transplantation. 2010 Jun 27;89(12):1511-7. doi: 10.1097/TP.0b013e3181db09e4.
8
Belatacept for kidney transplant recipients.用于肾移植受者的贝拉西普。
Cochrane Database Syst Rev. 2014 Nov 24;2014(11):CD010699. doi: 10.1002/14651858.CD010699.pub2.
9
Induction Immunosuppressive Therapy Use in Deceased Donor Kidney Transplantation: 11-Year Experience in Veracruz, Mexico.诱导免疫抑制疗法在尸体供肾移植中的应用：墨西哥韦拉克鲁斯的11年经验
Transplant Proc. 2016 Mar;48(2):600-4. doi: 10.1016/j.transproceed.2016.02.019.
10
Polyclonal versus monoclonal induction therapy in a calcineurin inhibitor-free immunosuppressive therapy in renal transplantation: a comparison of efficacy and costs.肾移植中无钙调神经磷酸酶抑制剂免疫抑制治疗中多克隆与单克隆诱导治疗：疗效与成本比较
Transplant Proc. 2015 Jan-Feb;47(1):45-9. doi: 10.1016/j.transproceed.2014.12.007.
引用本文的文献
1
Trends in Precision Medicine and Pharmacogenetics as an Adjuvant in Establishing a Correct Immunosuppressive Therapy for Kidney Transplant: An Up-to-Date Historical Overview.精准医学与药物遗传学在建立正确的肾移植免疫抑制治疗中的趋势及辅助作用：最新历史综述
Int J Mol Sci. 2025 Feb 24;26(5):1960. doi: 10.3390/ijms26051960.
2
The comparative efficacy and safety of basiliximab and antithymocyte globulin in deceased donor kidney transplantation: a multicenter cohort study.巴利昔单抗与抗胸腺细胞球蛋白在 deceased 供体肾移植中的疗效和安全性比较：一项多中心队列研究。
Kidney Res Clin Pract. 2023 Jan;42(1):138-148. doi: 10.23876/j.krcp.21.159. Epub 2023 Jan 31.
3
ATG-Fresenius increases the risk of red blood cell transfusion after kidney transplantation.ATG-Fresenius 增加肾移植后红细胞输血的风险。
Front Immunol. 2022 Dec 1;13:1045580. doi: 10.3389/fimmu.2022.1045580. eCollection 2022.
4
Antithymocyte globulin versus basiliximab induction for kidney transplantation in elderly patients: matched analysis within the Korean multicentric registry.老年患者肾移植中抗胸腺细胞球蛋白与巴利昔单抗诱导治疗的比较：韩国多中心登记研究中的匹配分析
Kidney Res Clin Pract. 2022 Sep;41(5):623-634. doi: 10.23876/j.krcp.21.310. Epub 2022 Jul 21.
5
[Thymoglobulin as induction treatment in kidney transplantants with low immunological risk: a Moroccan experience].[胸腺球蛋白在低免疫风险肾移植受者中的诱导治疗：摩洛哥经验]
Pan Afr Med J. 2022 Feb 17;41:138. doi: 10.11604/pamj.2022.41.138.23091. eCollection 2022.
6
Effects of Reduced-Dose Anti-Human T-Lymphocyte Globulin on Overall and Donor-Specific T-Cell Repertoire Reconstitution in Sensitized Kidney Transplant Recipients.减剂量抗人 T 淋巴细胞球蛋白对致敏肾移植受者整体和供者特异性 T 细胞 repertoire 重建的影响。
Front Immunol. 2022 Feb 25;13:843452. doi: 10.3389/fimmu.2022.843452. eCollection 2022.
7
Outcomes of Kidney Transplant Recipients with Sickle Cell Disease: An Analysis of the 2000-2019 UNOS/OPTN Database.镰状细胞病肾移植受者的结局：对2000 - 2019年美国器官共享联合网络/器官获取与移植网络数据库的分析
J Clin Med. 2021 Jul 11;10(14):3063. doi: 10.3390/jcm10143063.
8
Treatment optimization of maintenance immunosuppressive agents in pediatric renal transplant recipients.儿科肾移植受者维持性免疫抑制药物的治疗优化。
Expert Opin Drug Metab Toxicol. 2021 Jul;17(7):747-765. doi: 10.1080/17425255.2021.1943356. Epub 2021 Jun 29.
9
The Impact of Different Induction Immunosuppressive Therapy on Long-Term Kidney Transplant Function When Measured by Iothalamate Clearance.以碘他拉酸盐清除率衡量不同诱导免疫抑制疗法对肾移植长期功能的影响。
J Clin Med Res. 2020 Dec;12(12):787-793. doi: 10.14740/jocmr4369. Epub 2020 Dec 18.
10
Precision Medicine in Kidney Transplantation: Just Hype or a Realistic Hope?肾移植中的精准医学：只是炒作还是现实的希望？
Transplant Direct. 2021 Jan 7;7(2):e650. doi: 10.1097/TXD.0000000000001102. eCollection 2021 Feb.
本文引用的文献
1
Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance.活体供肾移植中使用他克莫司和霉酚酸酯并联合或不联合类固醇维持治疗的诱导疗法。
Clin J Am Soc Nephrol. 2015 Jun 5;10(6):1041-9. doi: 10.2215/CJN.08710814. Epub 2015 May 15.
2
OPTN/SRTR 2013 Annual Data Report: kidney.OPTN/SRTR 2013 年度数据报告：肾脏。
Am J Transplant. 2015 Jan;15 Suppl 2:1-34. doi: 10.1111/ajt.13195.
3
Association of antibody induction immunosuppression with cancer after kidney transplantation.肾移植后抗体诱导免疫抑制与癌症的关联。
Transplantation. 2015 May;99(5):1051-7. doi: 10.1097/TP.0000000000000449.
4
A randomized 2×2 factorial trial, part 1: single-dose rabbit antithymocyte globulin induction may improve renal transplantation outcomes.一项随机2×2析因试验，第1部分：单剂量兔抗胸腺细胞球蛋白诱导治疗可能改善肾移植结局。
Transplantation. 2015 Jan;99(1):197-209. doi: 10.1097/TP.0000000000000250.
5
The severity of acute cellular rejection defined by Banff classification is associated with kidney allograft outcomes.Banff 分类定义的急性细胞排斥反应的严重程度与肾移植结局相关。
Transplantation. 2014 Jun 15;97(11):1146-54. doi: 10.1097/01.TP.0000441094.32217.05.
6
Polyclonal antithymocyte globulin and cardiovascular disease in kidney transplant recipients.多克隆抗胸腺细胞球蛋白与肾移植受者的心血管疾病。
J Am Soc Nephrol. 2014 Jun;25(6):1349-56. doi: 10.1681/ASN.2013060663. Epub 2014 Feb 7.
7
The risk of acute rejection and the influence of induction agents in lower-risk African American kidney transplant recipients receiving modern immunosuppression.接受现代免疫抑制治疗的低风险非裔美国肾移植受者发生急性排斥反应的风险及诱导剂的影响。
Clin Transplant. 2014 Mar;28(3):292-8. doi: 10.1111/ctr.12311. Epub 2014 Jan 30.
8
Posttransplant monitoring of de novo human leukocyte antigen donor-specific antibodies in kidney transplantation.移植后新产生的人类白细胞抗原供体特异性抗体在肾移植中的监测。
Curr Opin Organ Transplant. 2013 Aug;18(4):470-7. doi: 10.1097/MOT.0b013e3283626149.
9
Alemtuzumab induction in renal transplantation.阿仑单抗诱导治疗肾移植。
N Engl J Med. 2011 May 19;364(20):1909-19. doi: 10.1056/NEJMoa1009546.
10
The impact of IL2ra induction therapy in kidney transplantation using tacrolimus- and mycophenolate-based immunosuppression.他克莫司和霉酚酸酯免疫抑制治疗中白细胞介素 2 受体激动剂诱导治疗对肾移植的影响。
Transplantation. 2010 Sep 27;90(6):639-44. doi: 10.1097/TP.0b013e3181ea6788.
Zotero 插件